ArticleHealth science reports2026
The Current Landscape and Future Prospects of Vaccine Manufacturing in Africa: Challenges, Innovations, and Opportunities: A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- From reactive trials to regional vaccine sovereignty: a pan-ebolavirus vaccine-readiness framework for East Africa's Sudan virus and Bundibugyo virus threats.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Africa has significant challenges in meeting its vaccination needs, including inadequate manufacturing capacity, infrastructure deficiencies, a scarcity of experienced personnel, regulatory hurdles, restricted access to technology and intellectual property. This review evaluates African vaccine manufacturing capacity, region-specific limitations, and highlights significant innovations and policy alternatives to promote vaccine autonomy and equitable public health results. Methods: A comprehensive narrative evaluation of the literature was done. We obtained prior papers from WHO publications, CDC publications, Google Scholar, Elsevier, PubMed, and EBSCOhost. The assessment examines the current status and future prospects of vaccine manufacturing in Africa, emphasizing obstacles, innovations, and possibilities. Results: Africa's vaccine manufacturing capacity is constrained by limited production infrastructure, a shortage of skilled personnel, and inadequate technical resources. These challenges are compounded by financial constraints, heavy reliance on donor support, and restricted access to technology transfer. In remote regions, regulatory fragmentation and weak cold chain infrastructure further hinder vaccine distribution. Promising innovations such as mRNA platforms, heat-stable formulations, and microarray patches offer potential breakthroughs, but progress in scaling up manufacturing remains slow despite international partnerships and funding support. To achieve vaccine self-sufficiency, Africa must strengthen its research ecosystem, build a skilled workforce, and expand domestic manufacturing capabilities. Conclusion: Africa's vaccine manufacturing capacity is at an important phase, requiring coordinated efforts to overcome long-standing barriers. Investment in local vaccine facilities, skilled personnel development, and strong regulatory framework are essential. Strengthening international partnerships while fostering local innovations will lead to self-reliance. Emphasis on One Health approaches can enhance disease surveillance and control. Adequate funding and political will are indispensable for sustained progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.